# A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

> **NCT02418845** · PHASE3 · COMPLETED · sponsor: **Symbiomix Therapeutics** · enrollment: 189 (actual)

## Conditions studied

- Bacterial Vaginosis

## Interventions

- **DRUG:** SYM-1219
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02418845
- **Lead sponsor:** Symbiomix Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-28
- **Primary completion:** 2015-10-05
- **Final completion:** 2015-12-05
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418845, "A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02418845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*